# Toripalimab Plus TPF Chemotherapy and Radiotherapy for LA-HPSCC

> **NCT04624308** · PHASE2 · UNKNOWN · sponsor: **Sun Yan** · enrollment: 81 (estimated)

## Conditions studied

- Hypopharyngeal Neoplasm Malignant Primary

## Interventions

- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT04624308
- **Lead sponsor:** Sun Yan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-30
- **Primary completion:** 2025-10-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 81 (ESTIMATED)
- **Last updated:** 2020-11-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04624308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04624308, "Toripalimab Plus TPF Chemotherapy and Radiotherapy for LA-HPSCC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04624308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*